Boehringer Ingelheim Corporation Release: Recruitment Complete for Two Pivotal Phase III Studies of nintedanib* in Patients With Idiopathic Pulmonary Fibrosis

Published: Sep 24, 2012

INGELHEIM, Germany--(BUSINESS WIRE)-- Boehringer Ingelheim is pleased to announce the last patients have been randomised into the Phase III sister trials assessing the efficacy and safety of nintedanib* (150 mg twice daily) in patients with idiopathic pulmonary fibrosis (IPF). The pivotal INPULSISTM Phase III trials continue as planned in study centres worldwide to assess the clinical outcomes in IPF patients treated with nintedanib*.

Back to news